DexCom Earnings Call Transcripts
Fiscal Year 2026
-
The event outlined a strategy for durable double-digit growth, driven by product innovation, expanded U.S. and international market access, and operational efficiency. Key initiatives include the G8 platform, expanded Medicare coverage, and a focus on multi-analyte sensing and preventative care.
-
Q1 2026 delivered 15% revenue growth, record global new patient starts, and margin expansion, driven by strong U.S. and international performance, new product launches, and expanded coverage. Guidance for 2026 was reaffirmed, with raised margin outlook and continued focus on innovation and access.
-
Leadership transition and a focus on technology, customer experience, and international growth are driving strategy. 2025 saw strong revenue and user growth, with 2026 guidance pointing to further margin expansion and new product launches, including the G8 sensor.
-
The conference highlighted robust financial growth, record new patient additions, and major product launches, including the G7 15-day sensor and Stelo. Strategic priorities focus on global market expansion, clinical evidence for broader coverage, and continued innovation in CGM technology.
Fiscal Year 2025
-
Q4 2025 revenue grew 13% year-over-year, driven by strong new customer demand and the G7 15-Day launch, with gross margin improving to 63.5%. 2026 guidance projects 11–13% revenue growth, continued margin expansion, and significant investments in innovation and global expansion.
-
Q3 2025 saw 20% organic revenue growth, record EPS, and strong Type 2 diabetes expansion. Gross margin declined due to higher scrap rates, but guidance was raised for revenue and margins. Product quality and supply chain issues are improving, with robust cash flow supporting share repurchases.
-
Strong new patient growth and expanding coverage in both U.S. and international markets are driving momentum, with type 2 non-insulin and basal insulin segments contributing significantly. Product improvements and strategic execution are expected to support strong double-digit growth into 2026.
-
Leadership transition is underway with a focus on expanding global coverage, launching innovative products like the 15-day sensor and G8, and sustaining strong double-digit growth. Stelo's rapid success and new Type 2 opportunities, along with operational efficiencies, are set to drive margin expansion.
-
Q2 2025 revenue grew 15% year-over-year, driven by expanded U.S. and international access, especially for type 2 non-insulin users. Gross margin declined due to shipping costs, but guidance was raised for the year. CEO succession to Jake Leach announced.
-
Q1 2025 saw 14% organic revenue growth, record new patient adds, and strong Type 2 non-insulin uptake, supported by expanded PBM coverage and new product launches. Gross margin declined due to supply chain costs, but full-year revenue guidance was reaffirmed, and a $750M share repurchase was announced.
-
Diabetes remains a major health and economic challenge, but CGM technology is driving improved outcomes and expanding market reach. Strong 2024 growth, new product launches, and expanded coverage position the company for continued momentum, with a 15-day CGM and further software innovation expected in 2025.
-
CGM adoption and coverage are expanding rapidly, with strong financial growth, new product launches, and a focus on type 2 diabetes and international markets. Stelo's launch and broader PBM coverage are driving access, while manufacturing scale and innovation support future margin expansion.
Fiscal Year 2024
-
Q4 2024 saw 8% organic revenue growth and a 25% increase in the global customer base, with strong international performance and expanding U.S. coverage. 2025 guidance targets 14% revenue growth, margin improvement, and a second-half launch of the 15 Day G7 system.
-
Q3 2024 saw 3% organic revenue growth, record new patient starts, and strong international acceleration, while U.S. revenue declined 2% amid channel shifts and rebate headwinds. Stelo's U.S. launch drove rapid adoption, and 2024 guidance was reaffirmed, with margin expansion and new product launches expected in 2025.
-
Management remains confident in high CGM market growth, with new products like Stelo expanding addressable segments. Execution challenges, especially in the DME channel, are being addressed through retraining and leadership focus, while a 2025 G7 15-day launch and ongoing innovation support long-term growth.
-
Q2 revenue grew 15% year-over-year but missed expectations due to sales force disruption, faster rebate eligibility, and DME channel share loss. Full-year guidance was lowered, with recovery expected by 2025 as new initiatives and product launches, including Stelo, ramp up.
-
Diabetes remains a major global health and economic challenge, with significant unmet needs. The company is expanding its CGM technology, launching Stelo for non-insulin and wellness users in August 2024, and growing its global reach and sales force. Management raised full-year guidance after strong Q1 results.